# BlueWillow Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bluewillow-biologics

- Industry: Biotechnology
- Headquarters: Ann Arbor, US
- Website: www.nanobio.com
- Total disclosed funding: $63M
- Latest round: Series A (May 6, 2018)
- Investors on record: 5

## About

BlueWillow Biologics Inc. is a clinical-stage company focused on vaccine development using its proprietary NanoVax® platform to enhance the prevention and treatment of infectious diseases.Founded in 2000 and headquartered in Ann Arbor, US, BlueWillow Biologics specializes in vaccine development. The company has conducted a total of 17 deals, with the most recent funding round being a VENTURE DEBT of USD 0.80 mn raised in August 2019. The CEO is Chad Costley, who has been pivotal in steering the company's strategic direction.BlueWillow Biologics specializes in vaccine development through its core technology, the NanoVax® platform. This intranasal adjuvant and antigen delivery system addresses the prevention and treatment of infectious diseases, targeting pathogens such as H5N1, seasonal and pandemic influenza, tuberculosis, COVID-19, respiratory syncytial virus (RSV), and herpes simplex virus. The NanoVax® platform is compatible with various antigens, enabling a comprehensive immune response. The company primarily serves healthcare providers and institutions involved in vaccination programs across North America and Europe, with end users being patients receiving immunizations against infectious diseases.BlueWillow Biologics generates revenue through collaborative partnerships and clinical trial engagements aimed at developing its vaccine candidates. The company collaborates with pharmaceutical firms, government agencies, and healthcare organizations to advance its intranasal vaccine technology, structured around research and development agreements that may include milestone payments. The flagship product, NanoVax®, represents a significant component of the company's portfolio, with revenue potential linked to successful product development and commercialization. Pricing plans are negotiated with partners in the healthcare sector, aligning with strategic goals.BlueWillow Biologics plans to leverage its recent VENTURE DEBT financing of USD 0.80 mn raised in August 2019 to support the design and launch of upcoming vaccine products. The company aims to expand its market presence in both North America and Europe by enhancing its partnerships with healthcare providers and institutions. Specific timelines for product releases and geographic expansions will be determined as development progresses and market conditions evolve.

## Funding rounds

- Series A, May 6, 2018, $10M — North Coast Technology Investors, Michigan Investment in New Technology Startups, Line Moon Ventures
- Series C, Oct 9, 2012, $11M — Venture Investors, Perseus
- Series B, Jul 8, 2009, $10M — Venture Investors, Perseus
- Series B, Feb 18, 2009, $12M — Perseus
- Series A, Aug 8, 2006, $20M — Perseus

## Investors

- Perseus (https://capitalatlas.ai/funds/perseus) — Series A, Series B, Series C
- Venture Investors — Series B, Series C
- North Coast Technology Investors (https://capitalatlas.ai/funds/north-coast-technology-investors) — Series A
- Michigan Investment in New Technology Startups (https://capitalatlas.ai/funds/michigan-investment-in-new-technology-startups) — Series A
- Line Moon Ventures — Series A